Physician profile
Vikas C Jain
NPI 1477555092
$261,034.19
in general payments reported to CMS, 2019-2025
50 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $36K · 2021: $39K · 2022: $37K · 2023: $21K · 2024: $43K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Food and Beverage: $10K · Consulting Fee: $9,030 · Travel and Lodging: $5,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,471.50 |
| Food and Beverage | $10,117.58 |
| Consulting Fee | $9,030.00 |
| Travel and Lodging | $5,438.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $96,306.94 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90,942.94 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $47,977.89 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Edwards Lifesciences Corporation | $10,969.96 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Inspire Medical Systems, INC. | $2,662.64 | 2023-2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $1,100.62 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $1,023.31 | 2021-2024 | Micra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,007.67 | 2019-2025 | Lifevest |
| Abbott Laboratories | $994.93 | 2019-2025 | Aveir, Na, Jot Dx |
| Novartis Pharmaceuticals Corporation | $968.14 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $699.92 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $694.08 | 2021-2025 | Verquvo |
| Pfizer INC. | $654.66 | 2019-2025 | |
| Novo Nordisk INC | $641.16 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $547.36 | 2019-2024 | Farxiga |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.